MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials. Check ...

Here, we explored how NMDARs signal in tLTD. We found that, regardless of frequency, L5 PC→PC tLTD relies on the non-ionotropic preNMDAR signaling pathway mediated by JNK2, which helps to resolve the ...